Peptide Radio Receptor Therapy sensitizes to immunotherapy by increasing expression of checkpoint molecules in in patients with neuroendocrine tumors

#3195

Introduction: Peptide Radio Receptor Therapy (PRRT) represents a standard treatment in patients with well-differentiated neuroendocrine tumors (NET G1/G2). Nevertheless, a lack of response is observed in 1/3 of patients after PRRT, suggesting that combination of PRRT with other therapies might increase its efficacy. The combination of PRRT with immune checkpoint inhibitors (ICI) might be promising, since radiation induced cell death can trigger antigen release and lead to activation of the immune system.

Aim(s): In this project, we are aiming to characterize the peripheral immune cell compartment of patients with NET that undergo PRRT in order to better understand how PRRT specifically acts on the immune system and to define patients that might benefit from treatment with ICI.

Materials and methods: Blood samples of patients with NET were drawn before and 2 days after PRRT and analysed by 24-color spectral flow cytometry.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Hammerich L

Authors: Büttne S, Wiedenmann B, Amthauer H, Tacke F, Roderburg C,

Keywords: neuroendocrine tumor, checkpoint blockade, PRRT, immunotherapy, spectral flow cytometry,